“…Although MSCs, with or without endothelial cells, have already been used by others to promote vascularization of implanted constructs and ischemic tissues in both preclinical and clinical settings [47,[65][66][67][68][69], the optimal MSC yielding the maximal therapeutic angiogenic response has yet to be determined. Results presented in this study and elsewhere suggest that thymus MSCs may be a promising candidate for therapeutic use [6,7].…”